Toward Safer Opioid Prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial

Gabriela Cedillo, Mary Catherine George, Richa Deshpande, Emma K T Benn, Allison Navis, Alexandra Nmashie, Alina Siddiqui, Bridget R Mueller, Yosuke Chikamoto, Linda Weiss, Maya Scherer, Alexandra Kamler, Judith A Aberg, Barbara G Vickrey, Angela Bryan, Brady Horn, Angela Starkweather, Jeffrey Fisher, Jessica Robinson-Papp, Gabriela Cedillo, Mary Catherine George, Richa Deshpande, Emma K T Benn, Allison Navis, Alexandra Nmashie, Alina Siddiqui, Bridget R Mueller, Yosuke Chikamoto, Linda Weiss, Maya Scherer, Alexandra Kamler, Judith A Aberg, Barbara G Vickrey, Angela Bryan, Brady Horn, Angela Starkweather, Jeffrey Fisher, Jessica Robinson-Papp

Abstract

Background: The 2016 U.S. Centers for Disease Control Opioid Prescribing Guideline (CDC Guideline) is currently being revised amid concern that it may be harmful to people with chronic pain on long-term opioid therapy (CP-LTOT). However, a methodology to faithfully implement the CDC guideline, measure prescriber adherence, and systematically test its effect on patient and public health outcomes is lacking. We developed and tested a CDC Guideline implementation strategy (termed TOWER), focusing on an outpatient HIV-focused primary care setting.

Methods: TOWER was developed in a stakeholder-engaged, multi-step iterative process within an Information, Motivation and Behavioral Skills (IMB) framework of behavior change. TOWER consists of: 1) a patient-facing opioid management app (OM-App); 2) a progress note template (OM-Note) to guide the office visit; and 3) a primary care provider (PCP) training. TOWER was evaluated in a 9-month, randomized-controlled trial of HIV-PCPs (N = 11) and their patients with HIV and CP-LTOT (N = 40). The primary outcome was CDC Guideline adherence based on electronic health record (EHR) documentation and measured by the validated Safer Opioid Prescribing Evaluation Tool (SOPET). Qualitative data including one-on-one PCP interviews were collected. We also piloted patient-reported outcome measures (PROMs) reflective of domains identified as important by stakeholders (pain intensity and function; mood; substance use; medication use and adherence; relationship with provider; stigma and discrimination).

Results: PCPs randomized to TOWER were 48% more CDC Guideline adherent (p < 0.0001) with significant improvements in use of: non-pharmacologic treatments, functional treatment goals, opioid agreements, prescription drug monitoring programs (PDMPs), opioid benefit/harm assessment, and naloxone prescribing. Qualitative data demonstrated high levels of confidence in conducting these care processes among intervention providers, and that OM-Note supported these efforts while experience with OM-App was mixed. There were no intervention-associated safety concerns (defined as worsening of any of the PROMs).

Conclusions: CDC-guideline adherence can be promoted and measured, and is not associated with worsening of outcomes for people with HIV receiving LTOT for CP. Future work would be needed to document scalability of these results and to determine whether CDC-guideline adherence results in a positive effect on public health. Trial registration https://ichgcp.net/clinical-trials-registry/NCT03669939 . Registration date: 9/13/2018.

Keywords: Chronic pain; HIV; Opioid prescribing guidelines; Opioids.

Conflict of interest statement

The authors report no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
CONSORT diagram for cluster-randomized clinical trial
Fig. 2
Fig. 2
CDC opioid prescribing guideline adherence. Each line represents an individual patient-participant

References

    1. Wide-ranging online data for epidemiologic research (WONDER). Centers for Disease Control and Prevention, CDC, National Center for Health Statistics. Updated 2020. Accessed Oct 2021,
    1. Overdose Death Rates. Centers for Disease Control and Prevention, CDC, National Center for Health Statistics. Updated January 29, 2021. Accessed Oct 2021,
    1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016;315(15):1624–1645. doi: 10.1001/jama.2016.1464.
    1. Olsen Y. The CDC guideline on opioid prescribing: rising to the challenge. JAMA. 2016;315(15):1577–1579. doi: 10.1001/jama.2016.1910.
    1. Wen LS, Lloyd MC. Prescribing opioids for chronic pain. JAMA. 2016;316(7):774. doi: 10.1001/jama.2016.9236.
    1. McAuliffe WE. Prescribing opioids for chronic pain. JAMA. 2016;316(7):774. doi: 10.1001/jama.2016.9239.
    1. Goldstick JE, Guy GP, Losby JL, Baldwin G, Myers M, Bohnert ASB. Changes in initial opioid prescribing practices after the 2016 release of the CDC guideline for prescribing opioids for chronic pain. JAMA Netw Open. 2021;4(7):e2116860. doi: 10.1001/jamanetworkopen.2021.16860.
    1. Fenton JJ, Agnoli AL, Xing G, et al. Trends and rapidity of dose tapering among patients prescribed long-term opioid therapy, 2008–2017. JAMA Netw Open. 2019;2(11):e1916271. doi: 10.1001/jamanetworkopen.2019.16271.
    1. Pedersen CA, Schneider PJ, Ganio MC, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing-2019. Am J Health Syst Pharm. 2020;77(13):1026–1050. doi: 10.1093/ajhp/zxaa104.
    1. Davis CS, Lieberman AJ. Laws limiting prescribing and dispensing of opioids in the United States, 1989–2019. Addiction. 2021;116(7):1817–1827. doi: 10.1111/add.15359.
    1. Barnett ML, Olenski AR, Thygeson NM, et al. A health plan's formulary led to reduced use of extended-release opioids but did not lower overall opioid use. Health Aff (Millwood) 2018;37(9):1509–1516. doi: 10.1377/hlthaff.2018.0391.
    1. Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA. 2021;326(5):411–419. doi: 10.1001/jama.2021.11013.
    1. Weeks WB. Hailey. JAMA. 2016;316(19):1975–1976. doi: 10.1001/jama.2016.10251.
    1. AMA backs update to CDC opioid prescribing guidelines. American Medical Association. Updated July 22, 2021. Accessed Oct 2021,
    1. Merlin JS, Westfall AO, Chamot E, et al. Pain is independently associated with impaired physical function in HIV-infected patients. Pain Med. 2013;14(12):1985–1993. doi: 10.1111/pme.12255.
    1. Sabin CA, Harding R, Bagkeris E, et al. Pain in people living with HIV and its association with healthcare resource use, well being and functional status. AIDS. 2018;32(18):2697–2706. doi: 10.1097/qad.0000000000002021.
    1. Knowlton AR, Nguyen TQ, Robinson AC, Harrell PT, Mitchell MM. Pain symptoms associated with opioid use among vulnerable persons with HIV: an exploratory study with implications for palliative care and opioid abuse prevention. J Palliat Care. 2015;31(4):228–233. doi: 10.1177/082585971503100404.
    1. Merlin JS, Long D, Becker WC, et al. Brief report: the association of chronic pain and long-term opioid therapy with HIV treatment outcomes. J Acquir Immune Defic Syndr. 2018;79(1):77–82. doi: 10.1097/qai.0000000000001741.
    1. Robinson-Papp J, Aberg J, Benn EKT, et al. Decreasing risk among HIV patients on opioid therapy for chronic pain: development of the TOWER intervention for HIV care providers. Contemp Clin Trials Commun. 2019;16:100468. doi: 10.1016/j.conctc.2019.100468.
    1. Fisher JD, Fisher WA, Misovich SJ, Kimble DL, Malloy TE. Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population. Health Psychol. 1996;15(2):114–123. doi: 10.1037//0278-6133.15.2.114.
    1. Navis A, George MC, Scherer M, Weiss L, Chikamoto Y, Robinson-Papp J. What physicians need to implement safer opioid prescribing: a qualitative study. J Opioid Manag. 2019;15(6):479–485. doi: 10.5055/jom.2019.0538.
    1. Anderson-Lewis C, Darville G, Mercado RE, Howell S, Di Maggio S. mHealth technology use and implications in historically underserved and minority populations in the United States: systematic literature review. JMIR Mhealth Uhealth. 2018;6(6):e128. doi: 10.2196/mhealth.8383.
    1. Scherer M, Weiss L, Kamler A, et al. Patient recommendations for opioid prescribing in the context of HIV care: findings from a set of public deliberations. AIDS Care. 2020;32(11):1471–1478. doi: 10.1080/09540121.2019.1705962.
    1. Navis A, George M-C, Nmashie A, Hoang E, Cedillo G, Robinson-Papp J. Validation of the safer opioid prescribing evaluation tool (SOPET) for assessing adherence to the centers for disease control opioid prescribing guidelines. Pain Med. 2020 doi: 10.1093/pm/pnaa138.
    1. Shoemaker-Hunt S, Sargent W, Jr, Swan H, et al. Developing clinical quality improvement measures aligned with the CDC guideline for prescribing opioids for chronic pain: an important strategy to support safer prescribing in primary care. Am J Med Qual. 2020 doi: 10.1177/1062860620944472.
    1. Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41(1):44–52. doi: 10.1097/01.qai.0000192000.15777.5c.
    1. Fisher JD, Cornman DH, Shuper PA, et al. HIV prevention counseling intervention delivered during routine clinical care reduces HIV risk behavior in HIV-infected South Africans receiving antiretroviral therapy: the Izindlela Zokuphila/Options for Health randomized trial. J Acquir Immune Defic Syndr. 2014;67(5):499–507. doi: 10.1097/qai.0000000000000348.
    1. Scherer M, Kamler A, Weiss L, et al. Toward safer opioid prescribing: effects of the TOWER intervention on HIV care providers. AIDS Care. 2021 doi: 10.1080/09540121.2021.1887444.
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol) 1995;57(1):289–300.
    1. Scherer M, Kamler A, Weiss L, et al. Toward safer opioid prescribing: effects of the TOWER intervention on HIV care providers. AIDS Care. 2021;34(4):440–445. doi: 10.1080/09540121.2021.1887444.
    1. Navis A, George MC, Scherer M, Weiss L, Chikamoto Y, Robinson-Papp J. What physicians need to implement safer opioid prescribing: a qualitative study. J Opioid Manag. 2018;15(9):479–485.
    1. Anderson D, Zlateva I, Khatri K, Ciaburri N. Using health information technology to improve adherence to opioid prescribing guidelines in primary care. Clin J Pain. 2015;31(6):573–579. doi: 10.1097/ajp.0000000000000177.
    1. Liebschutz JM, Xuan Z, Shanahan CW, et al. Improving adherence to long-term opioid therapy guidelines to reduce opioid misuse in primary care: a cluster-randomized clinical trial. JAMA Intern Med. 2017;177(9):1265–1272. doi: 10.1001/jamainternmed.2017.2468.
    1. Quanbeck A, Brown RT, Zgierska AE, et al. A randomized matched-pairs study of feasibility, acceptability, and effectiveness of systems consultation: a novel implementation strategy for adopting clinical guidelines for Opioid prescribing in primary care. Implement Sci. 2018;13(1):21. doi: 10.1186/s13012-018-0713-1.
    1. Witt TJ, Deyo-Svendsen ME, Mason ER, et al. A model for improving adherence to prescribing guidelines for chronic opioid therapy in rural primary care. Mayo Clin Proc Innov Qual Outcomes. 2018;2(4):317–323. doi: 10.1016/j.mayocpiqo.2018.09.004.
    1. Huang KTL, Blazey-Martin D, Chandler D, Wurcel A, Gillis J, Tishler J. A multicomponent intervention to improve adherence to opioid prescribing and monitoring guidelines in primary care. J Opioid Manag. 2019;15(6):445–453. doi: 10.5055/jom.2019.0535.
    1. Arizmendez NP, Kotovicz F, Kram JJF, Baumgardner DJ. Multimodal local opioid prescribing intervention outcomes in chronic noncancer pain management. J Am Board Fam Med. 2019;32(4):559–566. doi: 10.3122/jabfm.2019.04.180296.
    1. Gupta A, Lindstrom S, Shevatekar G. Reducing opioid overprescribing by educating, monitoring and collaborating with clinicians: a quality improvement study. Cureus. 2020;12(4):e7778. doi: 10.7759/cureus.7778.
    1. Marszalek D, Martinson A, Smith A, et al. Examining the effect of a whole health primary care pain education and opioid monitoring program on implementation of VA/DoD-recommended guidelines for long-term opioid therapy in a primary care chronic pain population. Pain Med. 2020;21(10):2146–2153. doi: 10.1093/pm/pnaa155.
    1. Stack M, Larouche V, Zhang Y, Warden D, Stack C, Klugiene EA. Effects of implementing a comprehensive opioid reduction protocol on overall opioid prescribing among patients with chronic, non-cancer pain in a rural family medicine clinic: a controlled cross-over trial. J Am Board Fam Med. 2020;33(4):502–511. doi: 10.3122/jabfm.2020.04.200060.
    1. Zgierska AE, Robinson JM, Lennon RP, et al. Increasing system-wide implementation of opioid prescribing guidelines in primary care: findings from a non-randomized stepped-wedge quality improvement project. BMC Fam Pract. 2020 doi: 10.1186/s12875-020-01320-9.
    1. Samet JH, Tsui JI, Cheng DM, et al. Improving the delivery of chronic opioid therapy among people living with human immunodeficiency virus: a cluster randomized clinical trial. Clin Infect Dis. 2021;73(7):e2052–e2058. doi: 10.1093/cid/ciaa1025.
    1. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20(5):309–318. doi: 10.1097/00002508-200409000-00005.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Wittchen HU. Reliability and validity studies of the WHO–Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res. 1994;28(1):57–84. doi: 10.1016/0022-3956(94)90036-1.
    1. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130(1–2):144–156. doi: 10.1016/j.pain.2007.01.014.
    1. Setnik B, Roland CL, Barsdorf AI, Brooks A, Coyne KS. The content validation of the Self-Reported Misuse, Abuse and Diversion of Prescription Opioids (SR-MAD) instrument for use in patients with acute or chronic pain. Curr Med Res Opin. 2017;33(6):1067–1076. doi: 10.1080/03007995.2017.1300142.
    1. Robinson-Papp J, George MC, Wongmek A, et al. The quantitative analgesic questionnaire: a tool to capture patient-reported chronic pain medication use. J Pain Symptom Manage. 2015;50(3):381–386. doi: 10.1016/j.jpainsymman.2015.03.013.
    1. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12(3):255–66. doi:10.1080/09540120050042891
    1. Hall MA, Zheng B, Dugan E, et al. Measuring patients' trust in their primary care providers. Med Care Res Rev. 2002;59(3):293–318. doi: 10.1177/1077558702059003004.
    1. Dyer N, Sorra JS, Smith SA, Cleary PD, Hays RD. Psychometric properties of the Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Clinician and Group Adult Visit Survey. Med Care. 50(suppl):S28–34. doi:10.1097/MLR.0b013e31826cbc0d
    1. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24(6):518–529. doi: 10.1002/nur.10011.
    1. Waugh OC, Byrne DG, Nicholas MK. Internalized stigma in people living with chronic pain. J Pain. 2014;15(5):550.e1–10. doi: 10.1016/j.jpain.2014.02.001.
    1. Brondolo E, Kelly KP, Coakley V, et al. The perceived ethnic discrimination questionnaire: development and preliminary validation of a community version1. J Appl Soc Psychol. 2005;35(2):335–365. doi: 10.1111/j.1559-1816.2005.tb02124.x.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner